Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting

    CALGARY, June 1 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ:   ONCY)
announced that interim results of a Phase II study of intravenous REOLYSIN(R)
in patients with sarcomas metastatic to the lung were presented May 30, 2009
at the American Society of Clinical Oncology (ASCO) annual meeting. The
meeting is being held in Orlando, Florida from May 29 to June 2, 2009.
    The presentation, entitled "A Phase II Study of Intravenous REOLYSIN
(Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue
Sarcomas Metastatic to the Lung" was delivered by Dr. Monica Mita, the study
principal investigator at the Institute of Drug Development (IDD), the Cancer
Therapy and Research Center at the University of Texas Health Science Center,
(UTHSC), San Antonio, Texas.
    The interim results demonstrate that the treatment has been well
tolerated, with 15 of 36, or 42% of evaluable patients experiencing stable
disease (SD) for more than 16 weeks, including five patients who have had SD
for more than 24 weeks. One patient had SD for more than 80 weeks. Oncolytics
reported on May 12, 2009, that full enrolment of 52 patients was completed, at
which time nine patients were continuing on study.
    "The ASCO data are very encouraging, both in terms of efficacy in
patients with sarcoma, and in those with other tumor histologies in whom the
IDD group are investigating various REOLYSIN regimens," said Dr. Frank Giles,
Director, IDD, and Deputy Director, CTRC at UTHSCSA.

    Additional REOLYSIN results presented

    Two additional poster presentations covering positive results of REOLYSIN
trials were also presented at the ASCO meeting on May 30, 2009.
    Dr. Johann de Bono and colleagues delivered a poster presentation
entitled "A Phase I Study of the Combination of Intravenous Reolysin (REO) and
Gemcitabine (GEM) in Patients (pts) with Advanced Cancer." The results, which
were previously announced in March 2009, demonstrated that the combination of
REOLYSIN and gemcitabine was well tolerated, and resulted in disease control
for a majority of the patients. Of the ten patients evaluable for response,
two patients (breast and nasopharyngeal) had partial responses (PRs) and/or
clinical responses and five patients had SD for 4-8 cycles, for a total
disease control rate (CR (Complete Response)+PR+SD) of 70%.
    Dr. Sanjay Goel and colleagues delivered a poster entitled "Dose
Escalation and Pharmacodynamic Study of Intravenous Administration of
REOLYSIN, a Live Replication Competent RNA Virus in Patients with Advanced
Solid Tumors." The results, which were previously announced in June 2007,
demonstrated that REOLYSIN was well tolerated. Of 18 patients treated in the
trial, eight demonstrated SD or better as measured by Response Evaluation
Criteria in Solid Tumors (RECIST) including a patient with progressive breast
cancer who experienced a PR (34% shrinkage in tumor volume).
    All three posters will be available today on the Oncolytics website at

    About Oncolytics Biotech Inc.

    Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics. Oncolytics'
clinical program includes a variety of Phase I/II and Phase II human trials
using REOLYSIN(R), its proprietary formulation of the human reovirus, alone
and in combination with radiation or chemotherapy. For further information
about Oncolytics, please visit www.oncolyticsbiotech.com

    This press release contains forward-looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements, including the implication of the materials
presented at this meeting with respect to REOLYSIN, the Company's expectations
related to the results of trials investigating delivery of REOLYSIN, and the
Company's belief as to the potential of REOLYSIN as a cancer therapeutic,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the availability of funds and resources to pursue research and
development projects, the efficacy of REOLYSIN as a cancer treatment, the
success and timely completion of clinical studies and trials, the Company's
ability to successfully commercialize REOLYSIN, uncertainties related to the
research and development of pharmaceuticals, uncertainties related to the
regulatory process and general changes to the economic environment. Investors
should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors are
cautioned against placing undue reliance on forward-looking statements. The
Company does not undertake to update these forward-looking statements, except
as required by applicable laws.

    %SEDAR: 00013081E

For further information:

For further information: Oncolytics Biotech Inc., Cathy Ward, 210, 1167
Kensington Cr NW, Calgary, Alberta, T2N 1X7, Tel: (403) 670-7377, Fax: (403)
283-0858, cathy.ward@oncolytics.ca; The Equicom Group, Nick Hurst, 325, 300
5th Ave SW, Calgary, Alberta, T2P 3C4, Tel: (403) 538-4845, Fax: (403)
237-6916, nhurst@equicomgroup.com; The Investor Relations Group, Erika Moran,
11 Stone St, 3rd Floor, New York, NY, 10004, Tel: (212) 825-3210, Fax: (212)
825-3229, emoran@investorrelationsgroup.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890